ITCC-078 Durvalumab
Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies
Promotor Name : AstraZeneca
Investigator Name : Dr Darren Hargrave
Trial registered on clinicaltrial.gov: NCT03837899
